Advanced Filters
noise

Hot Flash Clinical Trials

A listing of Hot Flash medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 344 clinical trials
J Julia Schwarz, MD

Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release

The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are: • Does targeted radiation therapy decrease recurrence of Dupuytren's contracture after treatment with Collagenase Clostridium Histolyticum? Participants will undergo: Release of Dupuytren's Contracture after Collagenase Clostridium Histolyticum injection …

45 years of age All Phase N/A

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.

18 - 89 years of age All Phase 2
L Lori Panu

Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis

The goal of this clinical trial is to characterize to understand the effects of a type of cell therapy called Chimeric Antigen Receptor T lymphocyte (CAR T) therapy in adult patients with the autoimmune disease dermatomyositis. This study will utilize a technology that modifies a type of white blood cell …

25 - 72 years of age All Phase 1
M Mohamed Maher Elashmawy, M.D, PHD.

Evaluating Ultrasound-Guided Needle Knife for Dupuytren's Contracture

This study aims to evaluate the efficacy and safety of ultrasound-guided needle knife dissection in treating Dupuytren's contracture. The procedure is designed to improve hund function and minimize complications associated with the conventional surgical methods.

18 years of age All Phase N/A
J Johan Engblom professor

Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons with Diabetes

Introduction Diabetic foot-ulcers leads to decreased quality of life, risk of major amputation, and resource demanding health-care. To minimize the risk of developing foot-ulcers, persons with diabetes are given the advice to daily inspect their feet and to apply skincare formulations. However, commercially available skincare products have rarely been developed …

18 years of age All Phase 4
P Pascal PILLET, Docteur

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

The MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM) in a phase II trial with the objective to obtain a better efficacy than the conventional combination methotrexate (MTX) and corticosteroids over the 24 week study period. …

3 - 18 years of age All Phase 2
K Katie Lewis

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy

18 - 65 years of age All Phase 1/2
M Meiping Lu, M.D

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and dose extension (Part B).

5 - 17 years of age All Phase 1

CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus

This is a phase I, open-label, single-arm, multicenter study to asess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in moderate or severe active systemic lupus erythematosus (SLE) subjects in China.

18 - 70 years of age All Phase 1
H Huiyu Nie

Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with abnormal activation of B lymphocytes, which may result in many adverse consequences and even death if not treated actively. Telitacicept, approved conditionally in China in March 2021, is a biologic agent targeting B lymphocyte stimulator (BLyS)and a proliferating inducing ligand …

18 - 75 years of age All Phase 4

Simplify language using AI